Colorectal Cancer Diagnostic Market with Focus on DNA-Based Tests: Industry Analysis (2018-2025)

DELHI, India - July 17, 2018 - PRLog -- A cancer is the abnormal growth of the cells that have the ability to invade or spread to the other parts of the body. Colorectal cancer begins when the healthy cells in the lining of the colon or rectum changes and grows out of control, forming a mass called tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. These changes usually take years to develop.

Screening for colorectal cancer is effective not only for early detection but also for prevention. Diagnosis of colorectal cancer through screening tends to occur 2-3 years before diagnosis of cases with symptoms. CRC Screening is broadly divided into Structural Examination and Stool Tests. Structural examination is further divide into Flexible Sigmoidography, Colonoscopy and Computed Tomographic Colonography, whereas Stool Tests are divided into Occult blood and DNA tests.

Colorectal cancer diagnostic market is expected to grow in future due to increasing disposable income, increasing ageing population and cancer incidences and rising healthcare expenditure. Key trends of this market include launch of branded and advanced diagnosis and technology innovation. However, there are some factors which can hinder the market growth including stringent legal norms, high cost, need for high quality of screening process and dearth of expertise.

The report "Colorectal Cancer Diagnostics Market with Focus on DNA-based Tests: Industry Analysis & Outlook (2018-2025)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia. The report profiles the key players of the market including Epigenomics, Exact Sciences Corporation, VoilitionRx Ltd and Quest Diagnostics.

List of Charts

Types of CRC Screening
Global Colorectal Cancer Incidences Forecast (2017-2022)
The U.S. CRC Screening Eligible Patient Volume Forecast (2018-2025)
The U.S. CRC Screening Receiving Patient Volume Forecast (2018-2025)
The U.S. CRC Screening Test Market Volume Forecast (2017-2022)
The U.S. CRC Screening Market Volume by Type (2017)
The U.S. CRC Colonoscopies Volume Forecast (2017-2022)
The U.S. CRC Sigmoidoscopies Volume Forecast (2017-2022)
The U.S. CRC FOBT Volume Forecast (2017-2022)
The U.S. CRC Stool Based DNA Test Volume Forecast (2017-2022)
The U.S. CRC Frontline Screening Tested Patient Volume Forecast (2021-2025)
The U.S. CRC Frontline Screening Test Sales Forecast by Value (2021-2025)
The U.S. CRC Cologuard Screening Test Sales forecast (2017-2022)
The U.S. CRC Epi proColon Screening Test Sales Value forecast (2017-2022)
Europe CRC Screening Eligible Patient Volume Forecast (2018-2025)
The UK CRC Screening Eligible Patient Volume Forecast (2018-2025)
Sweden CRC Screening Eligible Patient Volume Forecast (2018-2025)
Denmark CRC Screening Eligible Patient Volume Forecast (2018-2025)
Netherland CRC Screening Eligible Patient Volume Forecast (2018-2025)

List of Tables

CRC Death Averted per 1,000 Individuals Screened (2017)
Distribution of Colorectal Cancer Cases and Relative Survival
Types of Colorectal Cancer Screening Tests
Revenue Comparison of Key Players (2017)
DNA based CRC Screening Tests Comparison (2017)

For more Information:

http://www.konceptanalytics.com/Researchreport/colorectal-cancer-diagnostic-market-with-focus-on-dna-based-tests-industry-analysis-outlook-2018-2025-39524.aspx

Koncept Analytics

Vikas Gupta

(Business Development Manager)

FFCS-36, Ansal Plaza

Vaishali, Ghaziabad

U.P - 201010

Tele: +91-120-4130959

Mobile: +91-9871694789

Mail ID – vikas@konceptanalytics.com